Corvus Pharmaceuticals, Inc.
CRVS · XNASCIK 1626971fmd_18GCRKRPXFWRPX58T7DVJ6Z0CZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 29 | 46 | 39 | 38 | 32 | 29 | 24 | 17 | 19 | 34 |
| Total operating expenses | 37 | 57 | 49 | 49 | 44 | 39 | 33 | 23 | 28 | 43 |
| Operating income | (37) | (57) | (49) | (49) | (44) | (39) | (33) | (23) | (28) | (43) |
| Income before taxes | (36) | (56) | (47) | (47) | (6) | (43) | (41) | (22) | (59) | (13) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (36) | (56) | (47) | (47) | (6) | (43) | (41) | (22) | (59) | (13) |
| Net income | (36) | (56) | (47) | (47) | (6) | (43) | (41) | (27) | (62) | (15) |
| Net income to common shareholders | – | – | – | – | – | – | – | (27) | (62) | (15) |